GSE218060 decitabine T cell 2 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE218060_decitabine_T cell_2_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE218060_decitabine_T cell_2_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE218060_decitabine_T cell_2_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE218060_decitabine_T cell_2_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 891

Gene

uncharacterized LOC105375523

Gene

GAS1 adjacent regulatory RNA

Gene

long intergenic non-protein coding RNA 2669

Gene

uncharacterized LOC105377557

Gene

ALDH1L1 antisense RNA 1

Gene

CNTNAP2 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1549

Gene

SET pseudogene 11

Gene

RNA, 7SL, cytoplasmic 397, pseudogene

  • Gene

    long intergenic non-protein coding RNA 891


  • Gene

    uncharacterized LOC105375523


  • Gene

    GAS1 adjacent regulatory RNA


  • Gene

    long intergenic non-protein coding RNA 2669


  • Gene

    uncharacterized LOC105377557


  • Gene

    ALDH1L1 antisense RNA 1


  • Gene

    CNTNAP2 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1549


  • Gene

    SET pseudogene 11


  • Gene

    RNA, 7SL, cytoplasmic 397, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.